Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
55M
-
Number of holders
-
46
-
Total 13F shares, excl. options
-
14.2M
-
Shares change
-
+14.2M
-
Total reported value, excl. options
-
$408M
-
Value change
-
+$408M
-
Number of buys
-
46
-
Price
-
$29.17
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q2 2019
46 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2019.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 46 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.2M shares
of 55M outstanding shares and own 25.78% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (3.36M shares), Cormorant Asset Management, LP (1.87M shares), GILDER GAGNON HOWE & CO LLC (1.86M shares), RA CAPITAL MANAGEMENT, LLC (1.12M shares), Redmile Group, LLC (1.02M shares), PERCEPTIVE ADVISORS LLC (672K shares), FMR LLC (650K shares), MILLENNIUM MANAGEMENT LLC (553K shares), WELLINGTON MANAGEMENT GROUP LLP (406K shares), and JANUS HENDERSON GROUP PLC (400K shares).
This table shows the top 46 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.